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Abstract: 
Background: The origin of pro-inflammatory activation in chronic heart failure (HF) 
remains a matter of debate. Lipopolysaccharide (LPS) may enter the blood 
stream through the morphologically altered and leaky gut barrier. We 
hypothesized that lower LPS reactivity would be associated with worse survival 
as compared to normal or higher LPS reactivity.  
Methods: LPS responsiveness was studied in 122 patients with chronic HF 
(mean±SD: age 67.3±10.3 years, 24 female, New York Heart Association class 
[NYHA] class: 2.5±0.8, left ventricular ejection fraction [LVEF]: 33.5±12.5%) and 
27 control subjects of similar age (63.7±7.7 years, p>0.2). Reference LPS was 
added at increasing doses to ex vivo whole blood samples and tumour necrosis 
factor- (TNF was measured. Patients were subgrouped into high- and low-
responder status according to their potential to react to increasing doses of LPS 
(delta TNF secretion). The optimal cut-off value was calculated by receiver-
operator characteristic curve (ROC) analysis. 
Results: A total of 56 patients with chronic HF died from any cause during follow-
up. Cumulative mortality was 16.4% (95% CI 16.0-16.7%) at 24 months. The 
delta TNF value representing the optimal cut-off for the prediction of mortality 
was 1522 pg/mL (24 months) with a sensitivity of 49.3% (95% CI 37.2-61.4%) 
and specificity of 81.5% (95% CI 61.9-93.6%). LPS responder status remained an 
independent predictor of death after multivariable adjustment (hazard ratio 0.09 
for high- vs. low-responders, 95% CI 0.01-0.67, p<0.05). 
Conclusions: LPS responsiveness in patients with chronic HF is an independent 
predictor of death. Attenuated responsiveness to LPS may show impaired 
immune function.  
Introduction 
Chronic heart failure (HF) is a major public health challenge. Overactivity of 
neuroendocrine pathways is crucially involved in poor outcomes in this disease, 
although the introduction of beta-blockers, angiotensin converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers, and aldosterone antagonists into current 
HF treatment guidelines [1] has helped improving the patients’ prognosis. Novel 
avenues embrace repletion of iron deficiency and heart rate reduction with 
ivabradine. Overactivity of the immune system may be another worthwhile 
therapeutic target for implementing prognostic improvements [2].  
 
An important initial step in this regard is the development of an understanding of 
the interplay between neuroendocrine and inflammatory players. Preclinical data 
suggest that elevated serum levels of pro-inflammatory cytokines become 
detectable earlier in the course of the disease than, for example, elevated levels 
of angiotensin II [3]. Pro-inflammatory players embrace predominantly tumor 
necrosis factor  (TNF), interleukin (IL) 1 and IL-6, all of which have been 
shown to carry prognostic value in patients with chronic HF [4,5]. One of the 
strongest pathophysiological inducers of pro-inflammatory mediators is 
lipopolysaccharide (LPS), a cell wall constituent of gram-negative bacteria. Our 
group has previously shown that minute concentrations of LPS deemed 
pathophysiologically relevant are able to effectively induce TNF release in an ex 
vivo model of whole blood from patients with chronic HF [6]. Following the 
concept that LPS may enter the blood stream through the morphologically altered 
and leaky gut barrier (and possibly also through the pulmonary circulation) 
[7,8,9], we used LPS for our stimulation experiments. 
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Patients with longer duration of clinical HF may experience repeating LPS 
challenges, particularly during episodes of acute oedematous decompensation, 
and immune cells such as monocytes or lymphocytes may not be able to respond 
adequately to such repeated LPS exposures. In patients with sepsis, the term 
LPS desensitization has been proposed to describe this phenomenon, and it is a 
frequent finding in critically ill patients [10]. Similarly, our group has shown that 
LPS-desensitization may play a significant role in patients with HF [11]. 
Therefore, understanding the impact of LPS desensitization on survival may help 
in the development of novel therapies. An understanding of the pathophysiology 
of the trace element selenium may complement such approaches, as recent data 
suggest that inflammatory responses are selenium-dependent [12]. Several 
selenoproteins have anti-oxidant properties that take part in pivotal pathways 
inside leukocytes [13]. Additionally it has been shown that selenium 
supplementation suppresses pro-inflammatory gene expression in LPS-treated 
macrophages [14], as well as in a murine LPS-induced model for septic shock 
[15]. Selenium and selenoprotein levels are strongly decreased in patients with 
severe inflammatory pathologies [16,17,18] and are in discussion as prognostic 
markers for survival in septic [19,20] and renal cancer patients [21]. 
 
We hypothesized that lower LPS reactivity would be associated with worse 
survival as compared to normal or higher LPS reactivity in patients with chronic 
HF. In addition, we sought to elucidate the role of the selenium status in this 
context. 
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Methods 
 
Study population and follow-up 
Patients were recruited from the Royal Brompton Hospital specialist HF clinic 
(London, UK) as part of different studies into the responsiveness of ex vivo whole 
blood to LPS. Control subjects were recruited from patients’ relatives and hospital 
staff. Patients participated in projects designed to investigate novel biochemical 
markers and provided written informed consent. Patients were diagnosed 
according to guidelines issued by the European Society of Cardiology [1] together 
with documented objective evidence of left ventricular impairment (left ventricular 
ejection fraction [LVEF] <45%). Patients taking non-steroidal anti-inflammatory 
drugs (except low dose aspirin) or other immunomodulatory agents (e.g. steroids) 
were excluded. Subjects with clinical signs of infection, severe neuro-muscular 
disease, rheumatoid arthritis, significant renal dysfunction (serum creatinine >250 
mol/L), or cancer were also excluded, as were patients younger than 18 years of 
age and those with a history of unstable angina, myocardial infarction, or stroke 
within three months prior to the study.  
 
A total of 122 patients with chronic HF and 27 control subjects of similar age who 
participated in different previously published prospective studies of immune 
function were pooled [11,22,23,24]. Only subjects with available LPS stimulation 
data and a serum sample for the analysis of selenium were eligible for the 
present study. The clinical characteristics of these subjects are listed in Table 1. 
Patients and controls were followed-up for survival until March 2010 when the 
follow-up was censored. All patients were stable on medication for at least four 
weeks prior to being studied. Ninety-four percent of patients received diuretics, 
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97% angiotensin converting enzyme inhibitors or angiotensin receptor blockers, 
59% beta-blockers, 53% spironolactone, and 60% statins.  
 
Whole blood stimulation experiments 
Venous blood was collected from an antecubital vein after 15 minutes semi-
supine rest into LPS-free tubes (chromogenix AB, Sweden). Whole blood 
samples were diluted 1:1 with RPMI 1640 (Life Technologies Ltd., Paisley, UK) 
supplemented with 10 U/mL heparin (Leo Laboratories Ltd., Bucks, UK) to elicit a 
more pronounced TNF production than that of undiluted samples. E. coli-derived 
LPS (serotype 0111:B4, Sigma-Aldrich Co. Ltd., Irvine, UK) was added to achieve 
different final concentrations of 0.1, 1, 10 and 100 ng/mL. LPS was diluted in 
Hanks’ balanced salt solution. The addition of Hanks’ balanced salt solution alone 
served as control. Dilutions, aliquoting and stimulations were carried out under 
sterile conditions. A non-stimulated sample served as control. For stimulation, 
whole blood samples were incubated for 6 hours in a humidified atmosphere 
(37ºC, 5% carbon dioxide), unless otherwise indicated. Following incubation, 
samples were centrifuged at 1,500 rpm for 5 min. The supernatants were 
harvested and stored at -80C until final assessment. To assess LPS stimulatory 
capacity, we calculated the largest difference between the available LPS-
stimulated TNF values. The largest difference was usually present between the 
unstimulated sample and the sample stimulated with LPS at a dose of 10 or 100 
ng/mL. 
Cell viability was in all cases >90% as assessed using trypan blue exclusion. 
Trypan blue exclusion was performed using 100 μL of cell-rich suspension to 
which an equal volume of 0.4% trypan blue was added. The percentage of viable 
cells was calculated.  
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Determination of cytokines 
Serum levels of IL-6, TNF soluble tumor necrosis factor receptor-1 (sTNFR-1) 
and sTNFR-2 were determined using high-sensitivity enzyme-linked 
immunosorbent assay (ELISA) kits (Quantine HS, R&D systems, Minneapolis,  
USA). The respective limits of detection were 0.039 pg/mL, 0.106 pg/mL, 7.8 
pg/mL and 7.8 pg/mL. Levels of TNF from cell culture supernatant were 
measured using a commercially available standard ELISA kit (R&D systems, 
Minneapolis, USA). 
 
Selenium determination by total reflection X-ray fluorescence analysis  
Serum samples of 12 μL  were diluted with 12 µL of distilled water spiked with an 
internal gallium standard (2 g/L, Sigma-Aldrich). Samples were applied to quartz 
glass carriers and left to dry. Total reflection X-ray fluorescence analyses were 
performed using a Picofox S2 instrument (Bruker AXS Inc. Madison, Wisconsin, 
USA). The method was validated with a human serum Seronorm standard (Sero 
AS, Billingstad, Norway), and results were linear over a range of 1:2, 1:5 or 1:10 
dilutions. Mean selenium concentrations determined were in accordance with the 
certified content (168.7 ± 8.8 μg/L).  
 
Statistics 
All data are expressed as mean ± standard deviation (SD). Serum values of 
creatinine, total cholesterol, haemoglobin, selenium, IL-6, TNF, sTNFR-1, and 
sTNFR-2 were non-normally distributed and therefore log-transformed before 
analysis. This was also true for the LPS-stimulated TNF values. Repeated 
measures analysis of variance (ANOVA) and Student’s paired and unpaired t 
tests were used as appropriate. To calculate sensitivity and specificity, receiver-
operator characteristic curves (ROC) were constructed, and the area under the 
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curve (AUC) was calculated. The optimal cut-off value was defined as the 
calculated difference that yielded the highest product of sensitivity times 
specificity. 
 
The relationship of baseline variables with survival was assessed by Cox 
proportional-hazard analysis (single predictor and multivariable analysis). Hazard 
ratio (HR) and 95% confidence interval (CI) for risk factors and significance levels 
are given. To estimate the influence of risk factors on 24-month survival, Kaplan-
Meier cumulative survival curves were constructed for illustrative purposes and 
compared by the Mantel-Haenszel log-rank test. Statistical tests were performed 
using StatView version 5.0 (Abacus Concepts, Berkley, California, USA) and 
ROC curve analysis was performed using MedCalc 9.0 (MedCalc, Mariakerke, 
Belgium) software.   
 
Results 
 
Study population 
We analysed data from 27 control subjects and 122 patients with chronic HF. 
There were no significant differences in terms of age, gender, body mass index, 
or absolute number of white blood cells between patients and controls (Table 1). 
Serum selenium ranged from 51 to 318 µg/L in both groups with significantly 
lower levels in patients with chronic HF than in controls (p<0.05, Table 2). 
Significant differences were also found with regards to the distribution of 
neutrophils and lymphocytes (both p<0.05, Table 2). In addition we found 
significant differences in haemoglobin, serum sodium, creatinine, uric acid, 
cholesterol and several pro-inflammatory mediators (Tables 1 and 2).  
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Whole blood stimulation tests 
Upon stimulation with LPS at a dose of 0.1 ng/mL, 38.9% of control subjects and 
58.0% of patients with chronic HF released TNF, the highest amounts being 467 
and 1117 ng/mL, respectively. At an LPS dose of 1 ng/mL, 96.2% of controls and 
94.7% of patients with chronic HF released detectable amounts of TNF, the 
highest concentrations being 1726 and 3500 pg/mL, respectively. The 
corresponding numbers at an LPS dose of 10 ng/mL were 100% (3606 ng/mL) in 
controls and 98.1% (4557 pg/mL) in patients with chronic HF. Finally, at an LPS 
dose of 100 ng/mL 100% (2974 ng/mL) of control subjects and 98.8% (4034 
ng/mL) of patients with chronic HF released detectable amounts of TNF. Mean 
values of TNF secretion after stimulation with different concentrations of LPS in 
control subjects and patients with chronic HF are shown in Figure 1. 
 
In unstimulated whole blood samples, 4.3% of control subjects and 9.3% of 
patients with chronic HF released detectable amounts of TNF. The highest 
concentrations of TNF released from unstimulated samples were 56 and 821 
ng/mL, respectively.  
 
Survival analysis and LPS-responder status 
A total of 56 patients with chronic HF died from any cause during follow-up. At 12, 
24, 36, and 48 months, cumulative mortality was 10.7% (95% CI 10.4-11.0%), 
16.4% (95% CI 16.0-16.7%), 25.4 (95% CI 21.5-25.8%), and 32.0% (95% CI 
31.6-32.4%), respectively. At 24 months, the delta TNF value representing the 
optimal cut-off for the prediction of mortality was 1522 pg/mL, and it was 
associated with a sensitivity of 49.3% (95% CI 37.2-61.4%) and a specificity of 
81.5% (95% CI 61.9-93.6%). According to this cut-off value, 51 patients (45%) 
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were defined as high-, and 62 (55%) as low-responders. For comparison and 
according to the cut-off value derived from patients with HF, 9 (33%) controls 
were termed high-responders and 17 (63%) low-responders. TNF secretion by 
responder status is shown in Figure 2. Between high-responders and low-
responders there were no significant differences in terms of age, New York Heart 
Association (NYHA) class, LVEF, serum creatinine or any of the serum cytokine 
parameters in patients with chronic HF. High-responders had significantly higher 
relative counts of monocytes compared to controls (Table 2) and low responders 
(both p<0.0001, Table 3). Relative neutrophils counts were significantly higher in 
low-responders than in controls or high-responders (both p<0.001).  
 
Serum selenium ranged from 51 to 318 µg/L with significantly lower levels in 
patients with chronic HF than in controls (p<0.05, Table 2). In patients with HF, 
serum selenium was significantly higher in high-responders compared to low-
responders (p<0.05, Table 3). 
 
Using single predictor Cox proportional hazard analysis, we found that LPS 
responder status, NYHA class, serum creatinine, and serum selenium level all 
predicted survival. As shown in Table 4, Cox proportional hazard analysis 
demonstrated that high-responders had a lower risk of death in single predictor 
analysis during follow-up as compared to low-responders. Kaplan-Meier curves 
for cumulative survival are depicted in Figure 4.  
LPS responder status remained an independent predictor of death after adjusting 
for the strongest predictors of survival from single predictor analysis age, NYHA, 
creatinine and selenium (hazard ratio 0.12 for high- vs. low-responders, 95% 
confidence interval 0.02-0.93, p<0.05).  
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Discussion 
This is the first study to demonstrate that the responsiveness to LPS predicts 
survival in patients with chronic HF. Patients with a lower responsiveness towards 
LPS as assessed by TNFα secretion (low-responder) had a higher risk of death 
than those with a higher responsiveness (high-responder). Responder status 
remained an independent predictor of death after multivariable adjustment. In 
addition and in line with previous studies, patients with chronic HF showed higher 
serum levels of IL-6, sTNFR-1, and sTNFR-2. 
 
Looking at the results of this study, the first question concerns the factors that 
determine responsiveness to LPS. The second question is even more intriguing. 
It is related to the activity of the immune system itself and to the whys and 
wherefores that make a functioning immune system in chronic disease a 
necessity. The most obvious explanation for decreased LPS-responsiveness is a 
decrease in the number of TNFα releasing cells, predominantly monocytes. Their 
relative counts were significantly reduced in low-responders compared to high-
responders. Relative neutrophils counts were higher in the group of low-
responders. The relative counts of patients' lymphocytes were equally reduced in 
both high-responders and low-responders compared to controls. When 
comparing high-responders and low-responders, these findings were not 
associated with changes in serum levels of IL-6, TNFα, sTNFR-1, or sTNFR-2. 
 
Interestingly monocytes, presumably the most important source of TNFα in 
patients with chronic HF [25] are abundantly present in both low-responders and 
high-responders, and their number appears to be sufficient to maintain baseline 
TNFα serum levels. The reduction in lymphocytes, however, that was seen in 
patients with chronic HF as compared to control subjects represents an 
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attenuation in the patients’ specific immunity. The two factors combined, 
attenuated specific immunity together with unaltered or non-increased numbers of 
monocytes in low-responders may create a situation in which the body is not able 
to react adequately to additional pathological stimuli. 
  
In this context the role of selenium is not fully clear. Cells of the immune system 
may have an important functional need for selenium. Selenium is involved in both 
adaptive and innate immunity. The main effectors of innate immunity in acute 
inflammatory responses is the adherence of monocytes to the endothelium and 
their differentiation into macrophages. The role of selenium as an anti-
inflammatory element is linked to its effect on immune cells and especially to the 
macrophage signal transduction pathways [26]. The effect of selenium on 
immune cells and the role as an anti inflammatory actor may be mediated by its 
role in monocyte adhesion to endothelial cells and migration towards tissues [27]. 
Monocyte adhesion to the endothelial cells is modulated by L-selectin, a member 
of the selectin family, which facilitates neutrophil migration during inflammatory 
responses [28]. A powerful inducer of the expression of adhesion molecules is 
TNF-α, which is required in the recruitment of leukocytes across the endothelium 
[29]. Likewise, selenium is another important parameter for immune responses 
[30] as selenium has been suggested to protect neutrophils from oxygen-derived 
radicals produced to kill ingested foreign organisms [31]. Moreover, single 
nucleotide polymorphism affecting the expression of certain selenoproteins are 
associated with cytokine expression, e.g., the genotype of selenoprotein S 
directly affects basal tone of the proinflammatory cytokines IL-1, IL-6 and TNF 
even in healthy subjects [32]. Many clinical trials involving selenium are ongoing, 
but large trials that examine specific selenoproteins in cardiovascular diseases 
are necessary to clarify the effects of selenium and selenoproteins. Some data 
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suggest that patients with an activated immune response are in jeopardy of 
developing selenium deficiency and that they might benefit from selenium 
supplementation [33]. Given that cytokines appear to inhibit selenoprotein 
biosynthesis, as shown in a mouse model of sepsis [34], a combined regimen of 
anti-inflammatory medication along with a personalized selenium 
supplementation aiming to normalize the dysregulated immune system activity 
may positively affect chronic HF pathology. However, this theory needs to be 
tested in a prospective clinical trial and should be combined with a rigorous 
monitoring of immune cell responsiveness and resulting selenium status in order 
to avoid the risk of over-supplementation with this highly active micronutrient [35]. 
 
Conclusion 
We have shown that the responsiveness towards LPS as assessed by TNF 
secretion is an independent predictor of death. Additionally, serum selenium 
appears to play an important role in immune function and HF-dependent survival. 
These findings highlight the physiological importance of the selenium status for 
the immune system and HF-related mortality risk. Future studies should consider 
LPS responsiveness and consequently immune function along with the selenium 
status as meaningful enrolment criteria for immunomodulatory anti-cytokine 
studies.  
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 Figure 1 
LPS-stimulated TNF secretion from whole blood in control subjects and patients 
with chronic HF (* vs. unstimulated sample, + vs. LPS 0.1 ng/ml, # vs. LPS 1 
ng/ml, § vs. LPS 10 ng/ml. One symbol p<0.05, two symbols p<0.01, three 
symbols p<0.001, four symbols p<0.0001).  
 LPS concentration 
TNF 
Chronic HF 
Control 
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Figure 2 
Receiver-operator characteristic curve for sensitivity and specificity of the 
difference between the highest and the lowest LPS-stimulated TNF value to 
predict mortality during follow-up in patients with chronic HF (n=122, number of 
deaths = 56). 
 
Figure 3 
LPS-stimulated TNF secretion from ex vivo whole blood by LPS-responder 
group in control subjects and patients with chronic HF.  
 
LPS concentration 
TNF 
Chronic HF patients (low responder) 
Chronic HF patients (high responder) 
Control (low responder) 
Control (high responder) 
Figure 4 
Kaplan-Meier curve for cumulative survival in the high and low responder groups. 
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Table 1  
Baseline data of control subjects and patients with chronic HF. 
 Control 
subjects 
Chronic HF 
patients 
p-value 
Number (female) 27 (13) 122 (24) 0.002 
NYHA class  2.5 ± 0.8  
Aetiology 
(ischaemic/non-ischaemic) 
  
75 / 47 
 
LVEF (%)  33.5 ± 12.5  
Age (years) 63.7 ± 7.7 67.3 ± 10.3 0.09 
Haemoglobin (g/dL) 14.3 ± 1.1 13.4 ± 1.6 0.006 
Sodium (mmol/L) 139 ± 2.1 136 ± 3.4 0.002 
Potassium (mmol/L) 4.2 ± 0.3 4.3 ± 0.5 0.10 
Creatinine (mol/L) 81 ± 14 121 ± 43 <0.0001 
Uric Acid (mol/L) 313 ± 78 442 ± 128 <0.0001 
Cholesterol (mmol/L) 5.9 ± 0.8 4.7 ± 1.2 <0.0001 
HDL cholesterol (mmol/L) 1.5 ± 0.4 1.2 ± 0.4 0.002 
Table 2 
Baseline markers of immune function and inflammation (NS = non-significant with 
p>0.20) 
Control subjects Chronic HF patients   
(n=27) (n=122) 
p-value 
White Blood Cells  
(x 109/L) 
7.0 ± 1.7 7.6 ± 2.2 0.15 
Neutrophils (%) 59.8 ± 7.9 66.5 ± 8.9 <0.01 
Lymphocytes (%) 29.8 ± 6.0 21.2 ± 8.0 <0.0001 
Monocytes (%) 5.0 ± 1.2 5.6 ± 1.8 0.12 
Eosinophils (%) 3.2 ± 1.8 3.5 ± 2.3 NS 
Basophils (%) 0.8 ± 0.5 0.7 ± 0.4 NS 
CRP (mg/L) 8.5 ± 5.7 9.9 ± 7.6 NS 
IL-6 (pg/mL) 2.0 ± 2.2 4.7 ± 4.1 <0.01 
TNF (pg/mL) 4.0 ± 7.7 2.6 ± 2.7 0.16 
sTNFR-1 (pg/mL) 1220 ± 380 1838 ± 1085 <0.05 
sTNFR-2 (pg/mL) 1598 ± 478 2628 ± 1370 <0.01 
Selenium (µg/L) 108.9±17.8 98.6±32.2 <0.05 
 
Table 3 
Clinical characteristics and laboratory findings by LPS-responder group, patients 
with chronic HF only (NS = non-significant with p>0.20) 
  High responders 
(n=51) 
Low responders 
(n=62) 
p-value 
Age (years) 68.5 ± 8.6 66.6 ± 11.7 NS 
NYHA class 2.5 ± 0.8 2.5 ± 0.8 NS 
LVEF (%) 34.5 ± 13.8 33.3 ± 12.0 NS 
Haemoglobin (g/dL) 13.3 ± 1.8 13.4 ± 1.5 NS 
Creatinine (µmol/L) 118 ± 42  123 ± 46 NS 
Cholesterol 
(mmol/L) 
4.6 ± 1.1 4.8 ± 1.3 NS 
White Blood Cells  
(x 109/L) 
7.3 ± 1.9 8.0 ± 2.4 NS 
Neutrophils (%) 62.4 ± 7.3 69.7 ± 8.7 <0.001 
Lymphocytes (%) 22.6 ± 8.4 19.9 ± 7.5 0.09 
Monocytes (%) 6.4 ± 1.9 5.0 ± 1.4 <0.0001 
CRP (mg/L) 9.7 ± 6.5 10.1 ± 8.8 NS 
IL-6 (pg/mL) 4.2 ± 3.0 5.2 ± 4.8 NS 
TNF (pg/mL) 2.8 ± 2.6 2.3 ± 2.3 NS 
sTNFR-1 (pg/mL) 1979 ± 1152 1733 ± 1056 NS 
sTNFR-2 (pg/mL) 2773 ± 1186 2565 ± 1546 NS 
Selenium (µg/L) 107.6±43.0 91.8±20.8 <0.05 
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Table 4 
Single predictor and multivariable Cox proportional hazard models for death 
among 122 patients with chronic HF (24 month follow up). Hazard ratios with 95% 
confidence intervals are given. 
Variable Single 
predictor 
Multivariable 
Model 1 
Multivariable 
Model 2 
Multivariable 
Model 3 
Multivariable 
Model 4 
0.29 0.12 0.29 0.09 0.11 
0.10-0.90 0.02-0.93 0.10-0.88 0.01-0.67 0.01-0.86 
LPS Responder 
Status 
(high/low) 0.03 0.042 0.03 0.02 0.04 
1.05 1.03 1.06 1.05 
0.10-1.09 0.98-1.09 1.00-1.13 0.97-1.14 
Age (1 year 
increase) 
0.07 
  
0.27 0.06 0.27 
4.43 4.31 3.38 3.99 
2.35-8.38 1.89-9.84 1.74-6.56 1.73-9.17 
NYHA class (1 
class increase) 
<0.001 0.0005 0.0003 
  
0.001 
0.98 0.97 
0.94-1.02 0.93-1.02 
LVEF  
(1% increase) 
0.32 
   
0.27 
  
3.52 1.51 1.82 1.91 
1.79-6.93 0.65-3.51 0.86-3.84 0.88-4.12 
 Log creatinine  
(1 SD increase) 
0.0003 0.34 0.12 0.10 
  
0.43 0.79 0.77 
0.23-0.79 0.41-1.54 0.40-1.49 
Log Se  
(1 SD increase) 
0.0064 0.49 
    
0.43 
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